Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients

Trial Identifier: D3250R00113
Sponsor: AstraZeneca
NCTID:: NCT05603845
Start Date: February 2023
Primary Completion Date: March 2025
Study Completion Date: March 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000
Brazil, Sao Paulo São Paulo, Sao Paulo, Brazil, 05403-000